Literature DB >> 8466587

Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease, Alzheimer disease, and neurologically normal controls.

K Mizukawa1, E G McGeer, P L McGeer.   

Abstract

An autoradiographic study of labeled mazindol binding to presumed dopamine (DA) uptake sites in the striatum was done in 7 Parkinson (PD), 6 Alzheimer (AD), 1 Huntington disease (HD), and 4 neurologically normal cases. Large and significant decreases of specific binding were found in PD in both caudate (to 32% of control) and putamen (to 16%), with no significant effect in AD or HD. Nonspecific binding was a large proportion of total binding in all cases. In the 12 cases where both binding data and DA levels were available, they showed highly significant linear correlations in both caudate and putamen. Autoradiographic studies on D1, D2, and muscarinic binding sites in the PD, AD and control striata revealed no significant group differences.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8466587     DOI: 10.1007/bf03160027

Source DB:  PubMed          Journal:  Mol Chem Neuropathol        ISSN: 1044-7393


  4 in total

Review 1.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 2.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

3.  Differential Influence of Amyloid-β on the Kinetics of Dopamine Release in the Dorsal and Ventral Striatum of Rats.

Authors:  Valery N Mukhin; Ivan R Borovets; Vadim V Sizov; Konstantin I Pavlov; Victor M Klimenko
Journal:  Neurotox Res       Date:  2021-05-15       Impact factor: 3.911

4.  Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.

Authors:  Chandana Buddhala; Susan K Loftin; Brandon M Kuley; Nigel J Cairns; Meghan C Campbell; Joel S Perlmutter; Paul T Kotzbauer
Journal:  Ann Clin Transl Neurol       Date:  2015-09-12       Impact factor: 4.511

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.